## PLASMA INCIDENT REPORTING: HEPATITIS-B

## 1. Introduction

Between August and October, the inclusion of Hepatitis-B contaminated plasma in fractionation batches resulted in withdrawal and destruction of products to the approximate value of £1 million.

At the time of inclusion into fractionation, records showed the plasma to be negative for HBsAg although one donor had been under investigation for over 12 months without notification to BPL and two other plasma units were from known HBsAg positive donations where the red cells had been discarded but the plasma issued.

- 2. Table 1 summarises hepatitis reports for the last six years and details 1988 reports.
  - 1) Plasma reports for last five years:

1983	28 h	epatit	is reports from RTCs
1984	35	н	
1985	28	**	
1986	51	M	* •
1987	31	H	
1988	30		" to date from RTCs.

2) Hepatitis risk/infected plasma fractionated in last five years:

3) Breakdown of hepatitis reports in 1988:

Jan. 88	4 hepatitis contact reports (4 from Manchester) - Discarded 1 high ALT report (from Lewisham) - Discarded
Feb. 88	1 hepatitis B +ve pack from Mersey - returned to RTC
Mar. 88	3 hepatitis +ve past donations from Wessex, Leeds and Trent 1 raised ALT report from N.W. Thames - all discarded
Apr. 88	1 hepatitis report from Wessex - Discarded
May 88	1 hepatitis B report from N.W. Thames - Discarded 2 NANB reports from N.E. Thames - Discarded
June 88	No hepatitis reports
July 88	1 hepatitis contact from N.E. Thames - Discarded 3 NANB contacts from N.E. Thames - Discarded

Aug. 88

2 post RBC transfusion Hep.B + Hep.B markers in donors from N.W. Thames and Trent. Plasma fractionated from incidents and implicated product held/rejected/recalled.

1 electrolysis report from S.E./S.W. Thames.

68/12

Sep. 88 1 post RBC transfusion Hep.B from N.W. Thames - Discarded 1 hepatitis A report from Trent - Discarded

Oct. 88 1 hepatitis B +ve plasma pool at BPL - all implicated product discarded.

1 acupuncture report from N.W. Thames - Discarded 1 raised liver enzymes from Manchester - Discarded

2 hepatitis reports from N.W. Thames and Trent - Discarded.

Two donations received in August and two in October were included in fractionation pools.

## 3. Intermediate and Final Product Disposal

W88/363 8Y 3611 1877 vials all issued and all recalled Fraction V -> Albumin ADB 0044 and 0045 8821 bottles 250 ml 4.5% albumin - held Fraction II -> LF 0042A 16.5 kg) LF 0042B 17.5 kg) LF 0042C 17.5 kg ) held LF 0042D 15.5 kg) B+1 precipitate -> external researcher - informed D88/374 8Y 3614 1998 vials destroyed - not issued Fraction V LF 0044 273 kg - held Fraction II LF 0044A 24.5 kg - held LF 0044B 18.5 kg - held

PR88/31 8Y 3648 2237 vials destroyed - not issued Fraction V LF 0068 550 kg - held

- 4. The plasma incident in PR88/31 necessitate enquiry to eleven RTCs on 20th October. At the time of writing, six RTCs have replied.
  - 1 Centre has identified two HBsAg positive donations recorded at the Centre but sent to BPL
  - 1 Centre has identified two donations on which there are no recorded microbiological data. These donations were sent to BPL and included in pool PR88/31.

Both Centres with documentary failures are to be visited by BPL QC and Production staff.

5. Figures 1 and 2 show the fate of HBsAg in pool PR88/31. Unfortunately, the A+1 paste was destroyed before further fractionation to Fraction II and Fraction III.

This study is probably unique as a large-scale in-process validation of virus partition and separation using Hepatitis-B virus.

The calculated dose of virus in the start-pool was 10 mg.

6. GMP procedures for plasma testing and transfer must be reviewed if further losses and risks to product and patients are to be avoided.

The documentation of the incident was available to the Medicines Inspectorate at their recent inspection of BPL.

While the inclusion of virus contaminated plasma is serious, it is of real significance that an inspection of one random pool revealed two plasma units without any documentation on microbiological testing.

R. S. LANE, 31 October 1988.

			HEPATITIS BE ANTIGEN			
		Concentration Factor	Status	व्य/क्य	(mg)	Recovery (%)
START POOL		. 1	•	3	10.1	[100]
CRYOPRECIPITATE						
Extract with True buffer	CRYOSUPERNATANT				15	
CRYOEXTRACT	***************************************	. 29	•	0.6	0.08	0.75
Add heparin						
HEPARIN SUPERNATANT		. 32	•	0.7	0.07	0.73
Add glycine and NaCl	HEPARIN PRECIPITATE					ŧ
REPRECIPITATED FACTOR VIII	***************************************	. ND	ND	• .	-	) <b>-</b>
Dissolve in citrate saline						
CONCENTRATED FACTOR VIII		309		≤0 1	<b>≤</b> 0 001	≤0 01
Desall by gel Filtration						
DESALTED, FORMULATED PACTOR VIII	\$400,000 can company 00000 000000000000000000000000000000	. 193	<b>±</b>	€0.1	<b>\$0.001</b>	<b>\$0 01</b>
Filter		*				
REPULTERED PACTOR VIII	***************************************	_ 193		<b>≤</b> 0.1	≤0.001	≤0 01
Sterile filler						
STERILE FILTERED FACTOR VIE	***************************************	_ 138	<b>±</b>	<b>≤</b> 0.1	≤0.001	≤0.01
Bottle and freeze-dry						
PREEZE-DRIED FACTOR VIII	***************************************	_ 138	±	≤0.1	≤0.001	≤0.01
Heat at 80 C for 72 hours						
DRY-HEATED FACTOR VIII CONCENTRATE	********************************	138	ND	-	-	-

Concerntration factor calculated relative to the start pool assuming 100% recovery at each stage

FIGURE 1: PROCESS RUN 8Y 3648

68/15

<sup>#</sup> HBs is status: antigen detectable but at the very limit of assay sensitivity

,			EPATITIS BE ANTICEN			
		Concentration Factor	States	म्/म	(mg)	Recovery (%)
START POOL SP 3648	***********	1	•	3	10 1	[100]
START POOL SP 3649		-	•	< 0.1	< 9.35	-
CRYOSUP'NT 8Y 3648 CRYOSUP'NT 8Y 3849					**	
BY 3849  PYROGEN- PREE VATER						
START POOL LF 0088		0.49	•	1.2	7.9	78
PRECIPITATE		8.9	ND		•	•,
SUPERNATANT		0.42	+	0.45	. 3.6	36
PRACTION IV PRECIPITATE		21.2	Ю	. <del>-</del>	-	- ,
FRACTION IV SUPERNATANT		0.34	-	<0.1	<1	<10
CENTRAL I						
FRACTION V SUPERNATANT	*************	. 0.34	ND	•	-	
PRECIPITATE	*** *********	6.1	. 1	≦0.1	<b>\$1</b>	≨10

Concentration factor calculated relative to the start pool SP 3848 assuming 100% recovery at each stage

NO Not determined NOT TE

TESTER NO SAMPLE KUMICAGE

FIGURE 2: FRACTIONATION RUN LF 0068

68/16

<sup>#</sup> HBs Ag status : antigen detectable but at the very limit of assay sensitivity